Show simple item record

dc.contributor.authorOh, Eonjuen_US
dc.contributor.authorChoi, Il-Kyuen_US
dc.contributor.authorHong, JinWooen_US
dc.contributor.authorYun, Chae-Oken_US
dc.date.accessioned2017-05-01T19:27:42Z
dc.date.issued2017en_US
dc.identifier.citationOh, Eonju, Il-Kyu Choi, JinWoo Hong, and Chae-Ok Yun. 2017. “Oncolytic adenovirus coexpressing interleukin-12 and decorin overcomes Treg-mediated immunosuppression inducing potent antitumor effects in a weakly immunogenic tumor model.” Oncotarget 8 (3): 4730-4746. doi:10.18632/oncotarget.13972. http://dx.doi.org/10.18632/oncotarget.13972.en
dc.identifier.issnen
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:32630622
dc.description.abstractInterleukin (IL)-12 is a potent antitumor cytokine. However, immunosuppressive tumor microenvironments containing transforming growth factor-β (TGF-β) attenuate cytokine-mediated antitumor immune responses. To enhance the efficacy of IL-12-mediated cancer immunotherapy, decorin (DCN) was explored as an adjuvant for overcoming TGF-β-mediated immunosuppression. We designed and generated a novel oncolytic adenovirus (Ad) coexpressing IL-12 and DCN (RdB/IL12/DCN). RdB/IL12/DCN-treated tumors showed significantly greater levels of interferon (IFN)-γ, tumor necrosis factor-α, monocyte chemoattractant protein-1, and IFN-γ-secreting immune cells than tumors treated with cognate control oncolytic Ad expressing a single therapeutic gene (RdB/DCN or RdB/IL12). Moreover, RdB/IL12/DCN attenuated intratumoral TGF-β expression, which positively correlated with reduction of Treg cells in draining lymph nodes and tumor tissues. Furthermore, tumor tissue treated with RdB/IL12/DCN showed increases infiltration of CD8+ T cells and proficient viral spreading within tumor tissues. These results demonstrated that an oncolytic Ad co-expressing IL-12 and DCN induces a potent antitumor immune response via restoration of antitumor immune function in a weakly immunogenic murine 4T1 orthotopic breast cancer model. These findings provide new insights into the therapeutic mechanisms of IL-12 plus DCN, making it a promising cancer immunotherapeutic agent for overcoming tumor-induced immunosuppression.en
dc.language.isoen_USen
dc.publisherImpact Journals LLCen
dc.relation.isversionofdoi:10.18632/oncotarget.13972en
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354867/pdf/en
dash.licenseLAAen_US
dc.subjectoncolytic adenovirusen
dc.subjectIL-12en
dc.subjectdecorinen
dc.subjectTGF-βen
dc.subjectTregen
dc.titleOncolytic adenovirus coexpressing interleukin-12 and decorin overcomes Treg-mediated immunosuppression inducing potent antitumor effects in a weakly immunogenic tumor modelen
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalOncotargeten
dash.depositing.authorChoi, Il-Kyuen_US
dc.date.available2017-05-01T19:27:42Z
dc.identifier.doi10.18632/oncotarget.13972*
dash.contributor.affiliatedChoi, Il-Kyu


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record